期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

非小细胞肺癌免疫治疗进展 被引量：22

Advances in immunotherapy for non-small cell lung cancer
原文传递
导出
摘要 目前非小细胞肺癌仍是癌症死亡的主要原因。近年来，随着多项免疫治疗药物在临床试验中呈现出良好的治疗效果，非小细胞肺癌的免疫治疗目前正受到越来越多的关注。本文就当前非小细胞肺癌免疫疗法的原理、相关药物临床试验以及评价标准作一概述。 Lung cancer is the leading cause of cancer-related deaths worldwide.With promising results from early trials,immunotherapy has become an exciting approach in the treatment of non-small cell lung cancer.This article discusses the current status of immunotherapy in non-small cell lung cancer, clinical trials of related drugs,and evaluation criteria.
作者 陈闽江 王孟昭
机构地区 中国医学科学院北京协和医学院北京协和医院呼吸科
出处 《国际呼吸杂志》 2016年第18期1418-1423,共6页 International Journal of Respiration
关键词 非小细胞肺癌 免疫治疗 疗效评估 Non-small cell lung caneer Immunotherapy Evaluation of immune therapy
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献57

  • 1Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al.Cancer incidence and mortality patterns in Europe: estimatesfor 40 countries in 2012 [J] . Eur J Cancer, 2013, 49( 6) : 1374-1403. DOI: 10. 1016/j. ejca. 2012.12. 027.
  • 2Pao W,Girard N. New driver mutations in non-small-cell lungcancer [J] . Lancet Oncol, 2011, 12 (2): 175-180. DOI :10.1016/S1470-2045(10)70087-5.
  • 3Ettinger DS, Wood DE, Akerley W,et al. NCCN GuidelinesInsights: Non-Small Cell Lung Cancer, Version 4. 2016 [J] . JNatl Compr Cane Netw, 2016,14(3) :255-264.
  • 4Eton O, Legha SS, Bedikian AY, et al. Sequentialbiochemotherapy versus chemotherapy for metastaticmelanoma : results from a phase QI randomized trial [J] . J ClinOncol, 2002, 20(8) :2045-2052.
  • 5Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumabplus interferon alfa-2a for treatment of metastatic renal cellcarcinoma: a randomised, double-blind phase H trial [J].Lancet, 2007, 370(9605) : 2103-2111.
  • 6Aerts JG, Hegmans JP. Tumor-specific cytotoxic T cells arecrucial for efficacy of immunomodulatory antibodies inpatients with lung cancer [J] . Cancer Res, 2013, 73(8) : 2381-2388. DOI: 10.1158/0008-5472. CAN-12-3932.
  • 7Tartour E, Zitvogel L. Lung cancer: potential targets forimmunotherapy [J] . Lancet Respir Med, 2013,1(7): 551-563.DOI : 10.1016/S2213-2600( 13)70159-0.
  • 8Pardoll DM. The blockade of immune checkpoints in cancerimmunotherapy [J] . Nat Rev Cancer, 2012,12(4): 252-264.D()I:10.1038/nrc3239.
  • 9Jadus MR, Natividad J, Mai A, et al. Lung cancer: a classicexample of tumor escape and progression while providingopportunities for immunological intervention [J] . Clin DevImmunol, 2012, 2012 :160724. DOI: 10.1155/2012/160724.
  • 10Martin F, Apetoh L, Ghiringhelli F. Role of myeloid-derivedsuppressor cells in tumor immunotherapy [J].Immunotherapy, 2012, 4(1): 43-57. DOI :10. 2217/imt. 11.154.

二级参考文献19

  • 1Oji Y, Miyoshi S, Maeda H, et al. Overexpression of the wilms'tumor gene WT1 in de novo lung cancers[J]. Int J Cancer, 2002, 100(3): 297-303.
  • 2Hayashi S, Oji Y, Kanai Y, et al. Low wilms' tumor gene expressionin tumor tissues predicts poor prognosis in patients withnon-small-cell lung cancer[J]. Cancer Invest, 2012, 30(2): 165-71.
  • 3Elisseeva OA, Oka Y, Tsuboi A, et al. Humoral immune responsesagainst Wilms tumor gene WT1 product in patients withhematopoietic malignancies[J]. Blood, 2002, 99(9): 3272-9.
  • 4Makita M, Hiraki A, Azuma T, et al. Antilung cancer effect ofWT1-specific cytotoxic T lymphocytes[J]. Clin Cancer Res, 2002, 8(8): 2626-31.
  • 5Cheever MA, Allison JP, Ferris AS, et al. The prioritization of cancerantigens: a national cancer institute pilot project for the accelerationof translational research[J]. Clin Cancer Res, 2009, 15(17):5323-37.
  • 6eber E, Anderson WF, Kasahara N. Recent advances in retrovirusvector-mediated gene therapy: teaching an old vector new tricks[J].Curr Opin Mol Ther, 2001, 3(5): 439-53.
  • 7zuma T, Otsuki T, Kuzushima K, et al. Myeloma cells are highlysensitive to the granule exocytosis pathway mediated byWT1-specific cytotoxic T lymphocytes[J]. Clin Cancer Res, 2004,10(21): 7402-12.
  • 8Ohminami H, Yasukawa M, Fujita S. HLA class I-restricted lysis ofleukemia cells by a CD8(+)cytotoxic T-lymphocyte clone specificfor WT1 peptide[J]. Blood, 2000, 95(1): 286-93.
  • 9Ochi T, Fujiwara H, Okamoto S, et al. Novel adoptive T-cellimmunotherapy using a WT1-specific TCR vector encodingsilencers for endogenous TCRs shows marked antileukemiareactivity and safety[J]. Blood, 2011, 118(6): 1495-503.
  • 10Nagai K, Ochi T, Fujiwara H, et al. Aurora kinase A-specific T-cellreceptor gene transfer redirects T lymphocytes to display effectiveantileukemia reactivity[J]. Blood, 2012, 119(2): 368-76.

同被引文献240

引证文献22

二级引证文献196

国际呼吸杂志
2016年 第18期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部